Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07548021Phase 1Not Yet Recruiting

Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda

Role: collaborator

NCT05979207Phase 1Completed

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Role: collaborator

NCT05287893Phase 1Completed

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

Role: collaborator

NCT05507970Phase 1Completed

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Role: collaborator

NCT04310085Phase 1Completed

Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

Role: collaborator

NCT03707041Phase 1Completed

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Role: collaborator

All 6 trials loaded